GlassScriptPhysician profile
Patricia Corbo
NPI 1689048936
$2,969.57
in general payments reported to CMS, 2019-2025
23 companies · $917 in 2025
The $917 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $666 · 2024: $1,387 · 2025: $917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,853 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,853.19 |
| Education | $116.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $487.14 | 2023-2025 | Breztri, Airsupra, Saphnelo |
| Takeda Pharmaceuticals U.S.A., INC. | $400.01 | 2023-2025 | Glassia |
| Glaxosmithkline, LLC. | $386.23 | 2023-2025 | Trelegy Ellipta, Benlysta, Nucala |
| Mallinckrodt Hospital Products INC. | $237.17 | 2023-2025 | Acthar |
| Ucb, INC. | $212.89 | 2023-2024 | Cimzia |
| Genzyme Corporation | $186.22 | 2023-2025 | |
| Grifols USA, LLC | $118.05 | 2024-2025 | Prolastin-C Liquid |
| Ani Pharmaceuticals, INC. | $117.94 | 2023-2024 | Purified Cortrophin Gel |
| Amgen INC. | $117.72 | 2023-2024 | Enbrel, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.71 | 2023-2025 | Ofev, Stiolto Respimat |
| Regeneron Healthcare Solutions, INC. | $90.30 | 2024-2025 | Dupixent |
| Baxter Healthcare | $85.88 | 2024-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Monarch Airway Clearance System |
| Mylan Specialty L.P. | $69.57 | 2023-2024 | Yupelri |
| Lilly USA, LLC | $58.58 | 2023-2025 | Taltz, Olumiant, Zepbound |
| Viatris Specialty LLC | $48.71 | 2025 | Yupelri |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $43.11 | 2025 | Ohtuvayre |
| Pfizer INC. | $39.90 | 2024 | |
| Sobi, INC | $38.19 | 2023 | |
| Horizon Therapeutics Plc | $29.24 | 2023 | Krystexxa |
| Janssen Biotech, INC. | $27.65 | 2023 | Tremfya, Simponi Aria |
| Pulmonx Corporation | $21.29 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Inogen, INC. | $18.69 | 2024 | |
| Insmed, INC. | $17.38 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Corbo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.